Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…
Gilead to acquire cancer therapy developer Arcellx
A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018. Stephen Lam | Reuters…
Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly
Novo Nordisk stock fell 15% Monday after it said its next-generation weight loss drug didn’t meet its key…
Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal…
More drugs should be over-the-counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter”…
CVS Health (CVS) earnings Q4 2025
A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025. Justin Sullivan | Getty…
Pfizer’s monthly obesity injection drove shows promise in trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it…
Eli Lilly CEO David Ricks talks Medicare coverage of obesity pills
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major…
Eli Lilly plans $3.5 billion Pennsylvania plant for obesity drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Sept. 23, 2025. Antranik…